Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

[1]  David R. Jones,et al.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.

[2]  R. Kimmig,et al.  Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients , 2019, Cellular and Molecular Life Sciences.

[3]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[4]  P. Fasching,et al.  A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) , 2019, Clinical Cancer Research.

[5]  J. Baselga,et al.  Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial , 2019, JAMA oncology.

[6]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[7]  A. Bardelli,et al.  Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. , 2018, Cancer cell.

[8]  J. Baselga,et al.  Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. , 2018, Journal of Clinical Oncology.

[9]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[10]  T. Pons,et al.  Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies , 2018, Clinical Cancer Research.

[11]  Dejan Juric,et al.  Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Mortimer,et al.  The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.

[13]  O. Delattre,et al.  Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma , 2017, Clinical Cancer Research.

[14]  Norikazu Masuda,et al.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[15]  Donavan T. Cheng,et al.  Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing , 2017, BMC Medical Genomics.

[16]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[17]  R. Peach,et al.  Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator , 2017, Journal of clinical pharmacology.

[18]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[19]  A. Viale,et al.  Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.

[20]  Maurizio Scaltriti,et al.  PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D , 2017, Science.

[21]  J. Baselga,et al.  Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. , 2017, Cancer discovery.

[22]  D. Fabbro,et al.  Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention , 2017, Nature Communications.

[23]  G. Hortobagyi,et al.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. , 2016, JAMA oncology.

[24]  R. Motzer,et al.  A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma , 2016, The oncologist.

[25]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[26]  G. Hampton,et al.  Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant , 2016, Nature Communications.

[27]  E. Winer,et al.  A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[28]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[29]  M. Dowsett,et al.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer , 2015, Science Translational Medicine.

[30]  Carlos Caldas,et al.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.

[31]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[32]  N. Tunariu,et al.  Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.

[33]  Andrew Menzies,et al.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.

[34]  J. Reis-Filho,et al.  Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification , 2015, Genome Biology.

[35]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[36]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[37]  Michael G. Kharas,et al.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.

[38]  J. Ware,et al.  First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[39]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[40]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  S. Chandarlapaty,et al.  Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. , 2014, Cancer discovery.

[42]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[43]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[44]  C. Arteaga,et al.  Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation , 2013, Breast Cancer Research.

[45]  A. Wolff,et al.  The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[46]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[47]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[48]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[49]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[50]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Víctor J Cid,et al.  A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. , 2011, Human molecular genetics.

[52]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[53]  M. Jeschke.  Faculty Opinions recommendation of Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. , 2008 .

[54]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[55]  Leslie Roberts,et al.  A Proof of Principle , 2007, Science.

[56]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[57]  S Matsuno,et al.  Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. , 2000, Cancer research.

[58]  C Eng,et al.  Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. , 1998, Human molecular genetics.

[59]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[60]  M. Scaltriti,et al.  Mechanisms of Resistance to PI3K and AKT Inhibitors , 2018 .

[61]  Y. Yarden,et al.  Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways , 2018, Resistance to Targeted Anti-Cancer Therapeutics.

[62]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[63]  Adrian V. Lee,et al.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.

[64]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[65]  S. Hilsenbeck,et al.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.

[66]  N. Dubrawsky.  Cancer statistics , 2022 .